Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy (semaglutide) and Zepbound (tirzepatide) will not exceed $200.

Evernorth, the health services division of Cigna, is debuting a pharmacy benefit management program geared to make Wegovy and Zepbound more available to patients by capping the amount they spend ...

Evernorth, the health services division of The Cigna Group (NYSE: CI) announced a first-of-its-kind pharmacy benefit offering that make weight loss medications WEGOVY® and ZEPBOUND® more ...

Cigna's Evernorth is signaling that it will expand its GLP-1 medication offerings through the creation of Evernorth EnReachRx, a new patient support model for pharmacies that want to provide enhanced ...

An obesity drug called Zepbound won approval for use in adults from the Food and Drug Administration Wednesday, ushering in a new rival to Novo Nordisk's blockbuster Wegovy. Eli Lilly & Co., maker ...

Zepbound (tirzepatide) is a brand-name drug prescribed for weight loss, obstructive sleep apnea (OSA), and other uses in certain adults. Keep reading to learn more about getting Zepbound covered ...

Those who took Zepbound lost on average of 50 pounds, compared to 33 pounds lost among those who took Wegovy. That’s the equivalent of losing 20% of body weight with Zepbound, versus nearly 14% ...